Literature DB >> 33917519

Chronic Low Grade Inflammation in Pathogenesis of PCOS.

Ewa Rudnicka1, Katarzyna Suchta1, Monika Grymowicz1, Anna Calik-Ksepka1, Katarzyna Smolarczyk2, Anna M Duszewska3, Roman Smolarczyk1, Blazej Meczekalski4.   

Abstract

Polycystic ovary syndrome (PCOS) is a one of the most common endocrine disorders, with a prevalence rate of 5-10% in reproductive aged women. It's characterized by (1) chronic anovulation, (2) biochemical and/or clinical hyperandrogenism, and (3) polycystic ovarian morphology. PCOS has significant clinical implications and can lead to health problems related to the accumulation of adipose tissue, such as obesity, insulin resistance, metabolic syndrome, and type 2 diabetes. There is also evidence that PCOS patients are at higher risk of cardiovascular diseases, atherosclerosis, and high blood pressure. Several studies have reported the association between polycystic ovary syndrome (PCOS) and low-grade chronic inflammation. According to known data, inflammatory markers or their gene markers are higher in PCOS patients. Correlations have been found between increased levels of C-reactive protein (CRP), interleukin 18 (IL-18), tumor necrosis factor (TNF-α), interleukin 6 (IL-6), white blood cell count (WBC), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α (MIP-1α) in the PCOS women compared with age- and BMI-matched controls. Women with PCOS present also elevated levels of AGEs and increased RAGE (receptor for advanced glycation end products) expression. This chronic inflammatory state is aggravating by obesity and hyperinsulinemia. There are studies describing mutual impact of hyperinsulinemia and obesity, hyperandrogenism, and inflammatory state. Endothelial cell dysfunction may be also triggered by inflammatory cytokines. Many factors involved in oxidative stress, inflammation, and thrombosis were proposed as cardiovascular risk markers showing the endothelial cell damage in PCOS. Those markers include asymmetric dimethylarginine (ADMA), C-reactive protein (CRP), homocysteine, plasminogen activator inhibitor-I (PAI-I), PAI-I activity, vascular endothelial growth factor (VEGF) etc. It was also proposed that the uterine hyperinflammatory state in polycystic ovary syndrome may be responsible for significant pregnancy complications ranging from miscarriage to placental insufficiency. In this review, we discuss the most importance evidence concerning the role of the process of chronic inflammation in pathogenesis of PCOS.

Entities:  

Keywords:  CRP; chronic inflammation; insulin resistance; interleukins; polycystic ovary syndrome

Year:  2021        PMID: 33917519     DOI: 10.3390/ijms22073789

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  23 in total

1.  Association of PCOS with offspring morbidity: a longitudinal cohort study.

Authors:  Shu Qin Wei; Marianne Bilodeau-Bertrand; Nathalie Auger
Journal:  Hum Reprod       Date:  2022-08-25       Impact factor: 6.353

Review 2.  Personalized Nutrition in the Management of Female Infertility: New Insights on Chronic Low-Grade Inflammation.

Authors:  Gemma Fabozzi; Giulia Verdone; Mariachiara Allori; Danilo Cimadomo; Carla Tatone; Liborio Stuppia; Marica Franzago; Nicolò Ubaldi; Alberto Vaiarelli; Filippo Maria Ubaldi; Laura Rienzi; Gianluca Gennarelli
Journal:  Nutrients       Date:  2022-05-03       Impact factor: 6.706

Review 3.  Metabolic and Molecular Mechanisms of Diet and Physical Exercise in the Management of Polycystic Ovarian Syndrome.

Authors:  Giorgia Scarfò; Simona Daniele; Jonathan Fusi; Marco Gesi; Claudia Martini; Ferdinando Franzoni; Vito Cela; Paolo Giovanni Artini
Journal:  Biomedicines       Date:  2022-06-02

Review 4.  Associations Between Asthma and Polycystic Ovary Syndrome: Current Perspectives.

Authors:  Yue Xu; Zhi-Yang Zhou; Jie-Xue Pan; He-Feng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-05       Impact factor: 6.055

5.  Hypertension induces gonadal macrophage imbalance, inflammation, lymphangiogenesis, and dysfunction.

Authors:  Shobana Navaneethabalakrishnan; Brooke K Wilcox; Bethany L Goodlett; Malea M Murphy; Brett M Mitchell
Journal:  Clin Sci (Lond)       Date:  2022-06-17       Impact factor: 6.876

6.  Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition.

Authors:  Luigi Barrea; Giovanna Muscogiuri; Gabriella Pugliese; Giulia de Alteriis; Annamaria Colao; Silvia Savastano
Journal:  Nutrients       Date:  2021-11-02       Impact factor: 5.717

7.  Plasma Diaphanous Related Formin 1 Levels Are Associated with Altered Glucose Metabolism and Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Case Control Study.

Authors:  Xing Li; Mingyu Liao; Jiaqing Shao; Weixin Li; Liu Shi; Dong Wang; Juan Ni; Qiuyue Shen; Fan Yang; Guiliang Peng; Ling Zhou; Yuling Zhang; Zheng Sun; Hongting Zheng; Min Long
Journal:  Mediators Inflamm       Date:  2022-02-11       Impact factor: 4.711

Review 8.  Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing.

Authors:  Hosna Mohammad Sadeghi; Ida Adeli; Daniela Calina; Anca Oana Docea; Taraneh Mousavi; Marzieh Daniali; Shekoufeh Nikfar; Aristidis Tsatsakis; Mohammad Abdollahi
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

Review 9.  Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach.

Authors:  Himani Nautiyal; Syed Sarim Imam; Sultan Alshehri; Mohammed M Ghoneim; Muhammad Afzal; Sami I Alzarea; Emine Güven; Fahad A Al-Abbasi; Imran Kazmi
Journal:  Biomedicines       Date:  2022-02-24

10.  Association of Prx4, Total Oxidant Status, and Inflammatory Factors with Insulin Resistance in Polycystic Ovary Syndrome.

Authors:  Sahar Mazloomi; Nasrin Sheikh; Marzieh Sanoee Farimani; Shamim Pilehvari
Journal:  Int J Endocrinol       Date:  2021-06-22       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.